HUMAN CERVICAL CANCER 1 PROTOONCOGENE AND PROTEIN ENCODED THEREIN

Abstract: A human cervical cancer (1) protooncogene having a base sequence of SEQ ID:1 or a fragment thereof is overexpressed in various cancer tissues and can be used in diagnosing various cancers and an anti-sense gene complementary thereto can be used in treating cancers.

Description: HUMAN CERVICAL CANCER 1 PROTOONCOGENE AND PROTEIN ENCODED THEREIN Field of the Invention The present invention relates to a novel protooncogene and protein encoded therein, and more particularly, to a human cervical cancer 1 protooncogene and a protein derived therefrom, which can be used in diagnosis of various cancers. Background of the Invention Higher animals including man each carry approximately 100,000 genes, but only about 15% thereof is expressed, and characteristics of individual's biological process, e.g., genesis, differentiation, homeostasis, responses to stimuli, control of cell segmentation, aging and apoptosis(programmed cell death), are determined depending on which genes are expressed(s_e_e Liang, P. and A. B. Pardee, Science, 257: 967-971(1992)). Pathogenic phenomena such as tumorigenesis are caused by gene mutation which brings about changes in the mode of gene expression. Therefore, comparative studies of gene expressions in various cells have been conducted to provide bases for establishing viable approaches to the understanding of diverse biological phenomena. For example, the mRNA differential display(DD) method suggested by Liang and Pardee is effective in elucidating the nature of tumor suppressor genes, cell cycle-related genes and transcriptional regulatory genes that control apoptosis(s_e_£ Liang, P. and A. B. Pardee supra). Further, the DD method has been widely used in examining the interrelationship of various genes in a cell. It has been reported that tumorigenesis is caused by various genetic changes such as the loss of chromosomal heterozygosity, activation of oncogenes and inactivation of tumor suppressor genes, e g . p53 genefsee Bishop, J M , Cell, 64 235-248(1991), and Hunter, T , Cell 64: 249- 270(1991)) Further, it has been reported that 10 to 30% of human cancer arises from the activation of oncogene through amplification of protooncogenes Therefore, the activation of protooncogenes plays an important i ole in the etiology of many tumors and there has existed a need to identify protooncogenes The present inventor has endeavored to unravel examine the mechanism involved in the tumorigenesis of cervical cancer, and, has unexpectedly found that a novel protooncogene, human cervical cancer l(HCCR- l) is specifically overexpressed in cancer cells This protooncogene can be effectively used m diagnosis, prevention and treatment of various cancers, e g , leukemia lymphoma, kidney, liver, lung, ovary and uterine cervix cancers Summary of the Invention Accordingly, an object of the present invention is to provide a novel protooncogene and a fragment thereof Other objects of the present invention are to provide a recombinant vector containing said protooncogene or a fiagment thereof and a microorganism transformed therewith, a protein encoded m said protooncogene and a fragment thereof, a kit for diagnosis of cancer containing said protooncogene or a fragment thereof, a kit for diagnosis of cancer containing said protem or a fiagment thereof, an anti-sense gene having a base sequence complementary to that of said protooncogene or a fragment thereof, and a process for treating or preventing cancer by using said anti-sense gene In accordance with one aspect of the present invention, there is provided a novel protooncogene having the nucleotide sequence of SEQ ID No 1 or a fragment thereof In accordance with another aspect of the present invention, there is provided a recombinant vector containing said protooncogene or a fiagment thereof and a microorganism transformed with said vector In accordance with still another aspect of the present invention, there is provided a protein having the ammo acid sequence of SEQ ID No 2 or a fragment thereof derived from said protooncogene or a fragment thereof Brief Description of the Drawings The above and other objects and features of the present invention will become apparent from the followmg description of the invention, when taken m conjunction with the accompanying drawings which respectively show, Fig 1 the DD identification of altered gene expression in normal cervix tissue, primary cervical cancer tissue, metastatic lymph node tissue and CUMC-6 cervical cancer cells Fig 2 the prediction of hydrophobicity of transmembrane regions m the protooncogene of the present invention using TMPRED piogram Fig 3 the results of northern blot analyses for HCCR- 1 gene expressed in normal cervical tissues, cervical cancer tissues and cervical cancel cell lιnes(CaSkι and CUMC-6), Fig 4 the results of northern blot analyses for HCCR-1 gene expiessed in normal lung tissue and lung cancer cell lines (NCI-H358. NCI-H460 NC1- H441. NCI-H1299, NCI-H520, NCI-H2009, and NCI-H157), Fig 5 A the results of northern blot analyses for HCCR-1 gene expressed m normal human 12-lane multiple tissues, Fig 5B the results obtained with the same sample of Fig 5A hybridized with β-actin Fig 6A the results of northern blot analyses for HCCR-1 gene expressed m human cancer cell lines, Fig 6B the results obtained with the same sample of Fig 6A hybridized with β-actm Fig 7A the results of northern blot analyses foi HCCR- 1 gene expressed in human tumor tissues and their normal counterparts, Fig 7B the results obtained with the same sample of Fig 7Λ hybridized with β-actin Fig 8 a micrograph illustrating representative characteristics of in situ hybridized human cervical cancer tissues, Fig 9 a phase-contrast feature of monolayei -cultured wild type NIH/3T3 cells, Fig 10 a phase-contrast feature of monolayer-cultured HCCR- 1 cells. Fig 11 hematoxyhn-eosin staining of monolayer-cultured HCCR- 1 cells, Fig 12 a transmission electron micrograph illustrating representative characteristics of cultured HCCR-1 cells, Fig 13 tumoπgemcity of HCCR-1 cells in nude mouse, Fig 14 hematoxyhn-eosin staining of subcutaneous tumour nodules taken from nude mice, Fig 15 transmission electron micrographs illustrating representative characteristics of nude mice-derived subcutaneous tumour tissue, Fig 16 phase-contrast features of monolayer-cultured nude mice- derived HCCR-1 N cells, Fig 17 sodium dodecyl sulfate (SDS)-PAGE results showing protem expression patterns before and after the IPTG induction, Fig 18 the result of western blotting analysis of NIH/3T3 cells without transfectιon(wιld type), NIH/3T3 transfected with pcDNA3 vector alone(pcDNA3) and HCCR-1 cells, Fig 19 the result of western blotting analysis of human tumour tissues of kidney, lung, ovary and cervix and their normal counterparts, Fig 20 the immunohistochemical study of HCCR-1 -tiansfected MH/3T3 cells against reticulm fibers (x250), Fig 21 the expression of epithelial marker, keratin in HCCR-1 - transfected NIH/3T3 cells (x250), Fig 22 the expression of epithelial membrane antigen in HCCR- 1 - transfected NIH/3T3 cells (x250), Fig 23 the expression of mesenchymal markei, vimentin in HCCR-1 - transfected NIH/3T3 cells (x250), Fig 24 the PKC activities m NIH/3T3 cells without transfectιon(wιld- type), NIH/3T3 transfected with pcDNA3 vector alone(pcDNA3) and NIH/3T3 transfected with HCCR- 1 protooncogene (HCCR-1 cells). Fig 25 the telomerase activities m 293 cells, ÷RNase, NIH/3T3 cells without transfectιon(wιld-type), NIH/3T3 transfected with pcDNA3 vector alone(pcDNA3) and NIH/3T3 transfected with HCCR-1 protooncogene(HCCR- 1 cells). Fig 26A the result of RT-PCR amplification of HCCR- 1 cDNA in H- 358 lung carcinoma cell lines treated with anti-sense ohgodeoxynucleotides. Fig 26B the results obtained with the same sample of Fig 26A hybridized with β-actin Fig 27 growth curves of H-358 lung carcinoma cells tieated with sense, missense or anti-sense HCCR-1 ODN, and untreated parental cells, Fig 28 HCCR-1 protem expressions in fetal 16-(F16), 18-(F18), 20- (F20), postnatal 1-(P1), 7-(P7), 14-day(P14) and adult rat kidney tissue extracts, Fig 29 immunohistochemical staining of 20 day-old fetal rat kidney (x42), and Fig 30 differential-interference contrast microscopy of 18 day-old fetal rat kidney illustrating HCCR-1 immuno staining in the basolateral plasma membrane of medullary collecting duct (x220) Detailed Description of the Invention The novel protooncogene of the present invention, 1 e , human cervical cancel l(hereιnafter "HCCR-1 protooncogene"). consists of 2118 base pairs and has the DNA sequence of SEQ ID NO 1 In SEQ ID NO 1, the full open reading frame corresponding to base Nos 9 to 1088 is a protem encoding region and the predicted amino acid sequence derived therefrom is shown in SEQ ID NO 2 which consists of 360 amino acιds("HCCR-l protem") Further, the region corresponding to base lo Nos 9 to 83 of SEQ ID NO 1 encodes a signal peptide with the piedicted ammo acid sequence of ammo acid Nos 1 to 25 in SEQ ID NO 2 and the region represented by nucleotide No 435 to 494 of SEQ ID NO 1 encodes a single transmembrane domain having the predicted ammo acid sequence of amino acid Nos 143 to 162 of SEQ ID NO 2 This suggests that the 1 protooncogene of the present invention is a membrane-bound gene A single potential N-glycosylation sιte(correspondmg to base Nos 945 to 953 of SEQ ID NO 1 and ammo acid Nos 313 to 3 15 of SEQ ID NO 2) is present at the C-terminal side of the HCCR-1 protem, which suggests that HCCR- 1 protein is a type II membrane protem The polyadenylation signal 20 corresponds to the nucleotide Nos 2008-2012 of SEQ ID NO 1 The predicted extracellular domain of HCCR-1 corresponds to base Nos 495-1088 with the predicted amino acid sequence of ammo acid Nos 163-360 consisting of 198 ammo acids with 5 cysteme residues The predicted intracellular domain contains 117 amino acιds(correspondmg to nucleotide Nos 2 84-434 of SEQ ID NO 1 and ammo acid Nos 26-142 of SEQ ID NO 2) with two potential protein kinase C(PKC) phosphorylation sites at Seι-42 and Ser-48, and two potential N-mynstylation sites at Gly-34 and Gly-38 Further computer-assisted analyses indicate that HCCR-1 is markedly hydrophobic and possesses a characteristic single membrane -spanning domain and pie-secretory if) signal peptide as shown in Fig 2 In consideration of the degeneracies of codons and the preferred codons in a specific animal wherein the protooncogene of the present invention is to be expressed, various changes and modifications of the DNA sequences of SEQ ID NO 1 may be made, e g , in the coding area thereof without adversely altering the ammo acid sequence of the expressed protein, or in the non-coding area without adversely affecting the expression of the protooncogene Therefoie. the present invention also includes, in its scope, a polynucleotide having substantially the same base sequence as the inventive protooncogene, and a fiagment thereof As used herein, "substantially the same polynucleotide" refers to a polynuleotide whose base sequence shows 80% or more, pieferabh 90% or moie, most preferably 95% or more homology to the protooncogene of the present invention The protein expressed from the protooncogene of the present invention consists of 360 ammo acids and has the ammo acid sequence of SEQ ID NO 2 The molecular weight of this protem is about 40 kDa However, various substitution, addition and/or deletion of the ammo acid lesidues of protein ma be performed without adversely affecting the protein's function Further, a portion of the protein may be used when a specific purpose is to be fulfilled These modified ammo acids and fragments thereof are also included in the scope of the present invention Therefore, the present invention includes, in its scope, a polypeptide having substantially the same amino acid sequence as the protem derived from the oncogene of the present invention and a fragment thereof As used herein, "substantially the same polypeptide" refeis to a polypeptide whose amino acid sequence shows 80% or more, preferably 90% oi more, most preferably 95% or more homology to the ammo acid sequence of SEQ ID NO 2 The protooncogene, or the protem, of the present invention can be obtained from human cancer tissues or synthesized using a conventional DNA or peptide synthesis method Further, the gene thus prepared may be inserted to a conventional vector to obtain an expression vector, which may, in turn, be introduced into a suitable host, e g , an E coli or yeast cell, The cells transformed with a vector containing the HCCR- 1 protooncogene or a fragment thereof is hereinafter referred to a "HCCR-1 cell" The transformed host may then be used m producing the inventive DNA or protein on a large scale For example, E cυh JM 109 is transfected with HCCR- 1 protooncogene by using pGEM-T easy vector and the JM 109/HCCR- 1 was deposited on October 11, 1999 with the Korean Collection foi Type Cultures(KCTC)(Address Korea Research Institute of Bioscience and Bιotechnology(KRIBB), #52, Oun-dong, Yusong-ku. Taejon, 305-333, Republic of Korea) under the accession number, KCTC 0667BP, in accoi dance with the terms of Budapest Treaty on the International Recognition of the Deposit of Microorganism for the Purpose of Patent Procedure In preparing a vector, expression-control sequences, e , piomotei terminator, self replication sequence and secretion signal, aie suitably selected depending on the host cell used The overexpression of the protooncogene of the present invention occurs not in normal cervical and lung tissues but m cervical cancel tissues cervical cancer cell lines and lung cancer cell lines This suggests that the protooncogene of the present invention induces cervical and lung cancels Further, when a normal fibroblast cell, e g , NIH/3T3 cell line, is transfected with the protooncogene of the present invention, an abnormal cells is produced Morphological characterizations with optical and electronic microscopes show that the abnormal cell has the form of a tumor cell When the normal fibroblast cell transfected with the protooncogene of the present invention is injected into the posterial lateral aspect of a nude mouse tumorigenesis is observed after about 21 days from the injection, the tumoi size becoming 1 5 cm x 1 5 cm m 40 days By using hematoxyhn-eosin dye method, it can be confirmed that the tumor cells are cancerous The formation of the epithelial carcinoma can also be confirmed by using transmission electron microscopy and immunhistochemical staining methods In addition to epithelial tissues such as cervical and lung cancer tissues, the ovei expression of the protooncogene of the present invention is also observed in various other cancer tumors such as leukemia, lymphoma kιdne liver and ovarian cancers Therefore, the protooncogene of the piesent invention is believed to be a factor common to all forms of various cancel and it can be advantageously used in the diagnosis of various cancers and the production of a transformed animal as well as in an anti-sense gene therap> A diagnostic method that can be performed using the protooncogene of the present invention may comprise, for example, the steps of hybridizing nucleic acids separated from the body fluid of a subject with a probe containing the protooncogene of the present invention or a fiagment theieof and determining whether the subject has the protooncogene by using a conventional detection method in the art The presence of the protooncogene may be easily detected by labeling the probe with a radioisotope or an enzyme Theiefore, a cancer diagnostic kit containing the protooncogene of the present invention oi a fragment thereof is also included in the scope of the present invention A transformed animal produced by introducing the protooncogene of the present invention into a mammal, e g , a rat, is also included in the scope of the present invention In producing such a transformed animal, it is preferred to introduce the inventive protooncogene to a fertilized egg of an animal befoie the 8th cell cycle stage The transformed animal can be advantageously used in screening for carcinogens or anticancer agents such as antioxidants The present invention also provides an anti-sense gene which is useful in a gene therapy As used herein, the term "an anti-sense gene" means a polynucleotide comprising a base sequence which is fully oi partiall) complementary to the sequence of the mRNA which is transcribed fiom the protooncogene having the base sequence of SEQ ID NO 1 or a fragment thereof said nucleotide being capable of preventing the expression of the open reading frame(ORF) of the protooncogene by way of attaching itself to the protein- binding site of mRNA An example of the anti-sense gene of the present invention is a 18-meι HCCR-1 anti-sense ohgodeoxιnucleotιde(ODN) having the base sequence of SEQ ID NO 3 Therefore, the present invention also includes, m its scope, a polynucleotide comprising substantially the same base sequence as SEQ ID NO 3 and a fragment thereof The present invention also includes within its scope a process foi treating or preventing cancer in a subject by way of administering a therapeutically effective amount of the inventive anti-sense gene thereto In the inventive anti-sense gene therapy, the anti-sense gene of the present invention is administered to a subject m a conventional mannei to pi event the expression of the protooncogene For example, the anti-sense ODN is mixed with a hydrophobized poly-L-lysine denvative by electiostatic interaction in accordance with the method disclosed by Kim, J S et al (J Controlled Release, 53, 175-182(1998)) and the resulting mixed anti-sense ODN is administered intravenously to a subject The present invention also includes withm its scope an anti-cancei composition comprising the anti-sense gene of the present invention as an active ingredient, m association with pharmaceutically acceptable carrieis excipients or other additives, if necessary The pharmaceutical composition of the present invention is preferably formulated for administration by injection The amount of the anti-sense gene actually administered should be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age and weight of the individual patient, and the severity of the patient's symptoms The protein expressed from the inventive protooncogene may be used in producing an antibody useful as a diagnostic tool The antibody of the piesent invention may be prepared m the form of a monoclonal or polyclonal antιbod> in accordance with any of the methods well known m the art by using a protein having the ammo acid sequence of SEQ ID NO 2 or a fragment thereof Cancer diagnosis may be carried out using any of the methods known in the art e g , enzyme linked ιmmunosorbentassay(ELISA), radιoιmmunoassay(RlA), sandwich assay, western blot or immunoassay blot on polyacrylic gel to asses whether the protem is expressed in the body fluid of the subject Theiefore, a cancer diagnostic kit containing the protem having the ammo acid sequence of ^ SEQ ID NO 2 or a fragment thereof is also included m the scope of the piesent invention A continuously viable cancer cell line may be established by using the protooncogene of the present invention, and such a cell line may be obtained foi example, from tumor tissues formed on the back of a nude mouse by ) injecting fibroblast cells transformed with the protooncogene of the piesent invention The cell lines thus prepared may be advantageously used in searching for anti-cancer agents The following Examples and Test Examples are given for the puipose of illustration only, and are not intended to limit the scope of the invention Example 1 Cultivation of tumor cells and separation of total RNA Step 1 - 1 Cultivation of tumor cells For differential display of mRNA, normal cervical tissues, untreated primary cervical cancer tissues and metastatic common iliac lymph node tissues were obtained from cervical cancer patients who underwent ladical hysterectomy The human cervical cancer cell line used in the differential display method was CUMC-6 cell line described by Kim et al ,(Gynecol Oncol 62 230-240(1996)) 5 Cells from the above-described tissues and CUMC-6 were maintained on Waymouth's MB 752/1 medium (Gibco) supplemented with 2 mmol/L of glutamme, 100 IU/ml of penicillin, 100 μg/ml of streptomycin, and 10% of fetal bovme serum (Gibco) Only the cell suspensions with greater than 95% viability, as assessed by trypan blue dye exclusion described by FieshneyC'Culture of Animal Cells A Manual of Basic Technique" 2nd Ed , A R. Liss, New York(1987)) were used in the present experiments. Step 1-2 : Isolation of total RNA and differential display of mRNA Total RNAs were extracted from normal cervical tissues, primar cervical cancer tissues, metastatic common iliac lymph node tissues and CUMC-6 cells obtained in Step 1-1 using a commercial system (RNeasy total RNA kit) provided by Qiagen (Qiagen Inc., Germany) and the removal of DNA contaminants from the RNAs was accomplished using Message clean kit (GenHunter Corp., Brookline, MA). Example 2 : Differential display reverse transcription(DDRTVPCR Differential display reverse transcription was performed in accordance with the reverse transcription-polymerase chain reaction (RT-PCR) method described by Liang and Pardee(1992), supra, with minor modifications First, reverse transcription was carried out using 0.2 μg each of the total RNAs obtained in Step 1-2 of Example 1 and one of the three primers, i e.. H- T1 1G. H-T11C, or H-T11A, as anchored ohgo-dT primers (RNAimage kit. GenHunter Cor., MA, USA). Then PCR was conducted using the same anchored primers and one of the arbitrary 5' 13 mer (RNAimage primer sets 1-4, H-AP 1-32) in the presence of 0.5 mM [α- 35 S]-labeled dATP (1200 Ci/mmol). The PCR thermal cycle was repeated 40 times, the cycle being composed of: 95 ° C for 40 sec. 40 V for 2 min. and 72 ° C for 40 sec, and finally the reaction was carried out at 72 ° C for 5 min. PCR-amplified fragments were resolved in 6% polyacrylamide sequencing gels. Differentially expressed fragments were identified by inspection of autoradiograms. Band of more than 200 base pairs, CC214, were excised from the dried sequencing gel The CC214 cDNA was eluted by boiling for 15 mm and reamphfied with the same primer pairs and PCR conditions as used in the above amplification step except that no [α - 3S S]-labeled dATP and 20 μM dNTPs weie used Example 3 . Cloning The reamphfied CC214 PCR product obtained as above was inserted into the pGEM-T Easy vector using an TA cloning system (Promega, USA) in accordance with the manufacturer's instructions Step 3-1 Ligation 2 μl of the reamphfied CC214 PCR product obtained in Example 2, 1 μl of pGEM-T easy vector (50 ng), 1 μl of T4 DNA hgase 10X buffer solution and 1 μl of T4 DNA lιgase(3 weiss umts/μl, T4 hgase, Pi omega, USA) weie charged into a 0 5ml tube and distilled water was added thereto to a final volume of 10 μl The ligation reaction mixture was incubated overnight at 14 ° C Step 3-2 TA cloning transformation TA cloning transformation was performed using the following piotocol coh JM109(Promega, WI, USA) was incubated in 10 ml of LB broth(Bacto-trypton lOg, Bacto-yeast extract 5g, NaCl 5g) until the optical density at 600nm reached about 0 3 to 0 6 The cultured mixture was kept at 0 ° C for 10 minutes and centrifuged at 4000 rpm at 4 ° C for 10 minutes The supernatant was removed and cells were harvested The harvested cell pellet was exposed to 10ml of 0 IM CaCl 2 at 0 ° C for 30 minutes to 1 houi to obtain competent cells The resultant was centrifuged at 4000 rpm at 4 ° C foi anothei 10 minutes and the collected cells were suspended in 2ml of 0 IM CaCl 2 at 0 ° C 200 μl of the competent cell suspension was transferred to a microfuge tube and 2 μl of the ligation product obtained in Step 3-1 was added thereto. The mixture was incubated in a water bath at 42 ° C for 90 seconds and rapidly cooled to 0 ° C . Added thereto was 800 μl of SOC medium (Bacto-trypton 2.0g, 5 Bacto-yeast extract 0.5 g, IM NaCl 1 ml, IM KC1 0.25 ml, TDW 97 ml, 2M Mg 2 1 ml, 2M glucose 1ml) and the mixture was incubated at 37 V for 45 minutes at 220 rpm in a rotary shaking incubator. LB agar plates containing ampicillin(50ul/ml) were prepared by spreading 25 μl of X-gal (40mg/ml stock in dimethylformamide) on top of agar ) with a glass spreader. 25μl of the transformed cells thus obtained was spread thereon and the plates were incubated at a 37 ° C incubator overnight. White colonies were loaded on an LB agar plate containing ampicillin and transformed E. coir, i.e., JM109/ CC214 were selected and incubated in a terrific broth(TDW 900 ml, Bacto-trypton 12 g, Bacto-yeast extract 24 g, glycerol 4 ml. 0.17M ϋ KH 2 P0 4 , 0.72 N K 2 HP0 4 100 ml). Example 4 : Separation of recombinant plasmid DNA The CC214 plasmid DNA of the transformed E. coh was separated b\ employing Wizard I M Plus Minipreps DNA Purification Kit(Promega, USA) in accordance with the manufacturer's instructions. A portion of the plasmid DNA thus separated was treated with ECoRl enzyme and subjected to gel electrophoresis to confirm the insertion of CC214 partial sequence in the plasmid. Example 5 : Sequence Analysis of DNA The CC214 PCR product obtained in Example 2 was subjected to PCR in accordance with the conventional method and the cloned, reamphfied CC214 PCR fiagments were subjected to sequence analysis according to the dideoxy chain termination method using a Sequenase version 2 0 DNA sequencing kit (United states Biochemical, Cleveland, OH) in accoi dance with the manufacturer's instructions The base sequence of the DNA corresponds to nucleotide Nos 1883- 2088 in SEQ ID NO 1 and is designated "CC214" The differential display reverse transcription polymeiase chain leactιon(DDRT-PCR) of the 206 bp cDNA fragment, l e . CC214 obtained above was carried out using a 5' arbitrary primer H-AP21 and a 3' H-T 1 1 C :> anchored primer and resolved by electrophoresis Identification of alteied gene expression by DD in the primary cervical cancel, metastatic lymph node tissue and CUMC-6 cells is shown in Fig 1 As can be seen in Fig 1. the 206 bp cDNA fragment, l e , CC214 was expressed m the cervical cancer, metastatic tissue and CUMC-6 cervical cancer cells but not in the normal tissue ι> Example 6 . Full length cDNA sequence analysis of the HCCR- 1 protooncogene A bacteπophage λgtl l human lung embryonic fibroblast cDNA library 0 (see Miki, T et al , Gene, 83 137-146( 1989)) was screened by plaque hybridization with 32 P-labeled CC214 as a probe The full-length HCCR- 1 cDNA clone, containing a 2118 bp insert m pCEV-LAC vector was obtained from the human lung embryonic fibroblast cDNA library and registered at GenBank on November 5, 1999 under the accession number AF 195651 5 HCCR-1 clone inserted into λpCEN vector (see Miki, T et al . supia) was excised out of the phage in the form of the ampicillm-resistant pCEV-LAC phagemid vector (see Miki, T et al , supra) by Not I cleavage To make a HCCR-1 plasmid DΝA, pCEV-LAC vector containing HCCR-1 gene was ligated with T4 DΝA hgase and hgated clone was0 transformed into E coh JM109 The transformed E coh JM109/HCCR1 thus obtained was deposited on October 11, 1999 with the Korean Collection foi Type Cultures(KCTC)(Address Korea Research Institute of Bioscience and Bιotechnology(KRIBB), #52, Oun-dong, Yusong-ku, Taejon, 305-333, Republic of Korea) under the accession number, KCTC 0667BP, in accordance with the terms of Budapest Treaty on the International Recognition of the Deposit of Micioorganism for the Purpose of Patent Procedure The full sequence of HCCR-1 consists of 21 18 bp which is identified in SEQ ID NO 1 In SEQ ID NO 1. the full open reading fiame of the HCCR- 1 protooncogene of the present invention corresponds to nucleotides No 9 to 1088 and is predicted to encode amino acid sequence shown in SEQ ID NO 2 which consists of 360 amino acids Further, the region corresponding to nucleotide Nos 9 to 83 of SEQ ID NO 1 encodes a signal peptide having 25 ammo acids corresponding to ammo acid Nos 1 to 25 of SEQ ID NO 2, the region of nucleotide Nos 435 to 494 of SEQ ID NO 1 encodes a single transmembrane domain whose ammo acid sequence coπesponds to amino acid Nos 143 to 162 m SEQ ID NO 2 This indicates that the protooncogene of the present invention is a membrane-bound gene A single potential N-glycosylation sιte(correspondmg to base Nos 945 to 953 of SEQ ID NO 1 and amino acid Nos 313 to 3 15 of SEQ ID NO 2) is present at the C-terminal side of the HCCR-1 protem, which suggests that HCCR-1 is a type II membrane protein The polyadenylation signal corresponds to the nucleotide Nos 2008-2012 of SEQ ID NO 1 The predicted extracellular domain contains 198 ammo acids with 5 cysteme residues The predicted intracellular domain contains 117 ammo acιds(correspondmg to nucleotide Nos 84-434 of SEQ ID NO 1 and ammo acid Nos 26-142 of SEQ ID NO 2) with two potential PKC phosphorylation sites at Ser-42 and Ser-48, and two potential N-mynstylation sites at Gly-34 and Gly- 38 Further computer-assisted analyses indicated that HCCR-1 is markedly hydrophobic and possesses a characteristic single membrane-spannmg domain and pre-secretory signal peptide as shown in Fig 2 In Fig 2, the X-axis lepresents the ammo acid sequence number of the peptide of the piesent invention and the Y-axis, the hydrophobicity of the peptide Example 7 . Northern blot analysis of the HCCR-1 gene in various cells Total RNAs were extracted from various tissues and cell lines as in Example 1 To determine the level of HCCR-1 gene expression. 20 μg denatured total RNAs from each tissue or cell lines were electrophoresed through 1% formaldehyde agarose gel and transferred to nylon membranes (Boehrmgei- Mannheim, Germany) The blots were hybridized with a 32 P-labeled landom- pπmed HCCR- 1 full cDNA probe which was prepared using a redipπme 11 landom prime labeling system(Amersham, England) The northern blot analysis was repeated twice and the results were quantified by densitometry and normalized with β -actin Fig 3 shows the results of northern blot analyses for HCCR- 1 gene expressed in normal cervical tissues, cervical cancer tissues and cervical cancel cell lmes(CaSkι and CUMC-6) As can be seen in Fig 3, the transcription level of HCCR-1 is high in the cervical cancer tissues and cancer cell lines (CaSkι(ATCC CRL 1550) and CUMC-6), but very low oi undetactable in the normal cervical tissues Fig 4 shows the results of northern blot analyses for HCCR-1 gene expressed m normal lung tissues and seven lung cancer cell lines, 1 e H358(ATCC NCI-H358), H460(ATCC NCI-H460), H441(ATCC NCI-H441 ) H299(ATCC NCI-H299), H520(ATCC NCI-H520), H2009(ATCC NCI-H2009), and H157(ATCC NCI -H157) As shown in Fig 4, HCCR-1 transcription level in high level in lung cancer cell lines H358, H460, H1299, H520, and H157, but not detectable in the normal lung tissues Fig. 5 A shows the results of northern blot analyses for HCCR- 1 gene expressed in normal human 12-lane multiple tissues, brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and leukocyte tissues(Clontech). Fig. 5B shows the results obtained with the same samples hybridized with a β -actin probe to confirm mRNA integrity As can be seen in Fig. 5A. HCCR-1 mRNA (-2.1 kb) is weakly present or absent in many normal tissues, but the level of expression was high in normal kidnev tissue. Fig. 6 A shows the results of northern blot analyses for HCCR- 1 gene expressed in human cancer cell lines; HL-60, HeLa. K-562, MOLT-4. Raji. SW480, A549 and G361(Clontech). Fig. 6B shows the results obtained with the same samples hybridized with a β-actin probe to confirm mRNA integrity As can be seen in Fig. 6A, HCCR-1 is transcribed at a high level in the human leukaemia and lymphoma cell lines such as chronic myelogenous leukaemia K- 562. Burkitt's lymphoma Raji, lymphoblastic leukaemia MOLT-4 and promyelocytic leukaemia HL-60 as well as HeLa cells K-562, MOLT-4 and HL-60, in particular, show higher transcription levels as compared with normal leukocyte by factors of approximately 190, 90 and 70, respectively. HCCR-1 expression levels in colorectal cancer SW480. lung cancer A549 and melanoma G361 cell lines are lower than those of leukemia and lymphoma. Further, northern blotting analyses of the human kidney, liver, lung, ovary and cervix tumor tissues and their normal counterparts were carried out As shown in Fig. 7A, HCCR-1 was transcribed at a high level in the human cancer cells, while the expression of HCCR-1 gene is barely observable in the normal cells Fig. 7B shows the results obtained with the same samples hybridized with β-actin probe to confirm mRNA integrity. Example 8 . Micrograph of in situ hybridized Human Ceivical Cancer Tissues For in situ hybridization, human cervical cancer tissue was fixed in peπodate-lysine-paraformaldehyde, embedded in a wax according to the procedure described by Aim et a\ ( Am J Physwl 265. F792 - F801 (1993)) and sectιoned(5 μm) A full-length HCCR-1 cDNA fragment was used to synthesize a digoxigenm-labelled RNA probe RNA in situ hybridization was carried out with the anti-sense RNA probe which was prepared using a DIG RNA Labelling Kιt(Boehrmger Mannheim) The sense RNA probe was used as a negative control Fig 8 shows a micrograph illustrating representative characteristics of in situ hybridized human cervical cancer tissues As can be seen in Fig 8, the in situ hybridized cervical cancer tissues are confirmed to contain a high-level of HCCR- 1 gene No staining was detected m the surrounding normal fibrous tissues Example 9 Construction of expression vectors and transformation of cells Step 9- 1 Preparation of a vector containing HCCR- 1 An expression vector containing the coding region of HCCR- 1 was constructed as follows First, the entire HCCR- 1 cDN A obtained in Example 6 was inserted into the Sail restriction site of a prokaryotic expression vector, pCEV-LAC(s_e_e Miki, T et al , Gene, 83 137-146 (1989)) Then, the Sail fragment was isolated from the pCEV-LAC/HCCR- 1 vector Then, pcDNA3 (Invitrogen) was digested with Xho\ to make a compatible end with Sail The Sail fragment containing the full length HCCR-1 coding sequence was inserted into the ΛT oI-digested pcDNA3 Lipofectamme (Gibco BRL) was used to introduce the resulting pcDNA3/HCCR-l expression vector into NIH/3T3 cells(ATCC CRL 1658. USA), followed by selection in a medium supplemented with G418 (Gibco) The resulting NIH/3T3 cells transfected with HCCR-1 was designated "HCCR- 1 cells" Another population of NIH/3T3 cells containing pcDNA3 alone was prepared as a control and designated "pcDNA3 cells" Step 9-2 NIH/3T3 fibroblast cells transfected with the HCCR-1 protooncogene The wild type normal NIH/3T3 cell, a differentiated fibroblast cell line is a spmdle shaped cell having a long slender nucleus and a scanty amount of cytoplasm as shown in Fig 9 When HCCR-1 was expressed m the NIH/3T3 expressing HCCR-1 (HCCR-1 cells) obtained in Step 9-1, the cell shape changes into a polygonal form with an ovoid nucleus and plump cytoplasm, as shown in Monolayer cultured HCCR-1 -transfected NIH/3T3 cells which is stained with hematoxylin-eosm, exhibit nuclear pleiomorphism, distinct nucleoli, granular chromatm patterns, tumor giant cells and atypical mitotic figures as shown m Fig 11 For transmission electron mιcroscopy(TEM), the cells and tissues weie fixed with 2 5% glutaraldehyde m a phosphate buffer (pH 7 4) They weie then postfixed with a 2% osmium tetroxide Specimens were dehydrated in a graded series of ethanols and embedded in Epon 812 Ultrathin sections thereof weie stained with uranyl acetate and lead citrate, and photographed by TEM(JEOL 1,200 EX, Tokyo, Japan) The TEM picture shown m Fig 12 reveals that cultured tumoui cells have microvilli and well-developed organelles (inset) As can be seen in Fig 12, the HCCR- 1 cell has microvilli on the cell surface, lobulated nucleus with prominent nucleoli and well-developed rough endoplasmic retιcula(ιER) and Golgi complexes (circle) In Fig 12, the scale bar corresponds to 3 μm In higher magnification of the area indicated by circle (mset), the scale bai corresponds to 1 μm Example 10 Tumoπgenicity and metastasis of HCCR- 1 protooncogene in animal To analyze tumouπgenicity, 5 X 10 6 HCCR-1 cells weie injected subcutaneously into the posterior lateral aspect of the trunk of 9 mice (5-week- old athymic nu/nu on BALB/c background) Nude mice were sacrificed when the subcutaneous tumors reached 1 5-2 5 cm in diameter All 9 mice injected with HCCR-1 cells showed palpable tumois after 21 days as shown in Fig 13 Nude mice bearing HCCR-1 allografts display characteristics of an epithelial carcinoma Fig 14 shows hematoxylm-eosm staining of subcutaneous tumor nodules taken from the nude mice The sections of the tumour nodules revealed typical epithelial cell nests sepaiated by fibrous stroma Example 11 . Electron microscopy of HCCR-1 protooncogene - induced tumoi tissue and establishment of new cancer cell line Tumor tissues taken from the tumor nodules formed on the nude mouse of Example 10 were examined with an electron microscope, which revealed that tumor nodules showed well-developed organelles and tumoui cells aie connected by desmosomes(Fιg 15) As shown in Fig 15. the tumoi tissue consists of tightly adhered cells with intercellular junction (circle) In Fig 15 the scale bar corresponds to 3 μm In higher magnification of the area indicated by circle illustrating desmosome (inset), the scale bar corresponds to 0 5 μm The cells obtained from the above tumor tissue was cultuied in a conventional manner using 20% fetal bovine serum and the cultured cells weie designated HCCR- IN cells which have cytological features similar to HCCR- 1 cells in vitro as shown in Fig 16 Example 12 Determination of size of protem expressed after the transfection of /. coli with HCCR-1 protooncogene A portion of HCCR-1 protooncogene corresponding to nucleotide Nos 123-473 and predicted amino acid Nos 39-155 was inserted into the multiple cloning site of pET-32b(+) vector(Novagen) and the lesulting pET- 32b(+)/HCCR- l vector was transfected into E coli BL21(ATCC 47092) The transfected L coli was incubated using an LB broth medium in a rotary shaking mcubatoi, diluted by 1/100, and incubated for 3 hours ImM isopropyl β-D- thιogalacto-pyranosιde(IPTG, Sigma) was added thereto to induce the piotem synthesis The h coli cells m the culture were disrupted by somcation and subjected to gel electrophoresis using 12% sodium dodecyl sulfate(SDS) befoie and after the IPTG induction Fig 17 shows the SDS-PAGE lesults which exhibit a piotem expression pattern of the E coli BL21 strain transfected with pET-32b(+)/HCCR- l vector After the IPTG induction, a significant protein band was observed at about 35kDa This 35kDa fused protem contained an about 20kDa Tπx-Tag thioredoxm protein expressed from a gene in pET-32b(+) vectoi Example 13. Production of antibody The 35 kDa fused protem isolated from the L coli BL21 strain transfected with pET-32b(+)/HCCR-l vector in Example 12 was purified by using a His-Bmd Kit (Novagen) Immunoblottmg of the purified peptide confirmed the presence of a major amount of a 35kDa protein Then, two 6-week old Sprague-Dawley rats each weighing about 150 g were each subcutaneously immunized with 1 mg of the peptide thus obtained, weekly for 3 times Blood samples were obtained from the immunized rats and centrifuged to obtain a polyclonal serum The anti-HCCR- 1 activity of the polyclonal serum was determined and confirmed by enzyme-linked immunosorbent assay(ELISA)(l : 10,000) Example 14 : Immunoblot confirming Antibody specificity For western blot analysis, those cells identified in Figs. 18 and 19 were harvested and lysed in a Laemmli sample buffer in accordance with the method described by Laemmli(Nature 221 x 680-685 (1970)). The cellular proteins were separated by 10% SDS-PAGE and then electroblotted onto nitrocellulose membranes. The membranes were incubated with the rat polyclonal anti- HCCR- 1 serum prepared in Example 13 for 16 h. After washing, the membranes were incubated with a blocking solution containing 1 : 1.000 dilution of peroxidase-conjugated goat anti-rat immunoglobulin (Jackson ImmunoResearch) as a secondary antibody. Proteins were revealed by an ECL-Western blot detection kit (Amersham). As shown in Fig. 18, HCCR-1 protein is overexpressed in HCCR- 1 cells, while only faint bands are observed for the wild type and cells transfected with the vector alone(pcDNA3). This result illustrates the specificity of the anti- HCCR- 1 antibodies in the polyclonal serum. Further, the HCCR-1 antibody in the polyclonal serum recognized approximately 40 kDa protein in human protein extracts from different tissues As shown in Fig. 19, human tumor tissues including carcinomas of the kidney, lung, ovaiy and cervix showed increased HCCR-1 protein expression when compared with their normal counterparts. Example 15: Immunohistochemistry The tumor nodules formed on the nude mouse of Example 9 were incubated with anti-vimentin, anti-keratin, anti-EMA(epithelial membrane antigen) antibodies (DAKO) and polyclonal antibody raised against HCCR-1, respectively Then, lmmunohistochemistry was carried out on 5 μm- cryosections of the incubated tumor nodules Binding of primary antibody was visualized by biotinylated secondary antibody, avidm, biotinylated horseradish peroxidase and AEC(Ammoethyl Carbaxzole Substrate Kit) as the chromogen(HISTOSTAIN-BULK KITS Zymed) The immunohistochemical study revealed that HCCR-1 tiansfection into NIH/3T3 cells caused the conversion of the cell nature from mesenchymal to epithelial The cell nests were enveloped by reticuhn fibei s as shown in Fig 20 The cells showed coexpression of epithelial markers, such as keratm(Fιg 21 ) and epithelial membrane antigen (Fig 22) and of the mesenchymal markei vιmentm(Fιg 23) Example 16. Protein kinase C and telomerase activity assays To ensure that HCCR-1 modulates the protein kinase C(PKC) activity in cells, PKC assay was performed using wild-type NIH/3T3 cells. pcDNA3- containmg NIH/3T3 cells and HCCR-1 -transfected NIH/3T3 cells piepaied in Step 9- 1 of Example 9 PKC activity was measured using the SιgnaTECT 1 Protem Kinase C Assay System (Promega) according to the manufacturer's instructions PKC activity was defined as the difference of the amounts of PKC incorporated into substrate per minute in the absence and presence of phosphohpids Each value is the means ± s d of three independent experiments The result in Fig 24 shows that the PKC activity of HCCR-1 - transfected NIH/3T3 cells is about 10-fold higher than the wild-type To explain the tumorigenesis of HCCR-1, telomerase activities in wild- type NIH/3T3 cells, pcDN A3 -containing NIH/3T3 cells and HCCR-1- transfected NIH/3T3 cells prepared in Step 9-1 of Example 9 were measured using the telomerase PCR-ELISA kit (Boehrmger Mannheim) according to the manufacturer's instructions Human telomerase-positive immortalized human kidney cells (293 cells) provided in the kit were used as a positive control Used as a negative control was the 293 cells pretreated with RNase (^RNase) Assays were performed with an extract amount equivalent to 1 x 10 3 cells Results in Fig 25 show the average mean optical densιty(OD) values from foui separate experiments (means + s d ) Consistent with the pievious study (Holt, S E . Wright, W E and Shay J W Mol Cell Biol 16, 2932-2939 (1996). wild-type NIH/3T3 cells showed detectable telomerase activity HCCR-1 gene transfection raised the telomerase activity by a factor of about 7 as compared with the wild-type cells The high telomerase activity of the 293 cells was nullified by pretreatment with RNase Example 17. Cell cycle experiments Wild-type and HCCR-1 -transfected NIH/3T3 cells cultured in a DMEM medium at mid-log phase were growth arrested by incubation in a DMEM medium containing 0 5% bovine calf serum for 36 h Cells to be analyzed foi the DNA content were harvested following trypsimzation, and fixed in 70% ethanol Fixed cells were then stained with propidmm iodide as described by Hedley(. /ovι Cytometrγ, DNA Analysis from Paraffin- em bedded Blocks Darzynkiewicz, Z & Cπssman, H A eds , Academic Press, San Diego 1990) First, 50 μg/ml of a propidmm iodide staining solution (Sigma) and 100 units per ml of RNase A (Boerhinger Mannheim) were added to 2 x 10 6 cells After incubation for 1 h, the cellular DNA content was determined by fluorescence analysis at 488 nm using a FACS Caliber (Becton Dickinson) A minimum of 1 x 10 4 cells per sample was analyzed with Modfit 5 2 software In order to study whether there was an alteration in the growth properties of HCCR-1 -transfected NIH/3T3 cells, cell cycle profiles were examined. The cell contents of the wild type NIH/3T3 cells and HCCR- 1 transfected NIH/3T3 cells(mid-log phase) in G 0 /G,, S, G 2 /M phases were measured and the results are shown in Table I. Table I As can be seen from Table I, the percentage of wild-type and HCCR- 1 - transfected NIH/3T3 cells in the S-phase was 20.6% and 31.5%. respectiveK (mid-log phase). These results suggest that there was a significant shift of the cell population out of the G 0 /G,-phase into the S-phase in HCCR- 1 transfected NIH/3T3 cells. To assess the serum-dependent cell cycle progression, cells were cultured in 0.5% bovine calf serum for 36 h. After incubation, cells were released with 20% bovine calf serum and harvested at indicated times The cell contents of wild type NIH/3T3 cells and HCCR-1 transfected N1H/3T3 cells in G 0 /G,, S, G 2 /M phases at indicated times were measured and the results are shown in Table II. Table II As can be seen from Table II, few cells remained in the S-phase in wild- type cells measured at 0 h (8%) In contrast, a considerable number of HCCR- 1 cells measured at 0 h were still in the S-phase (21 8%), suggesting that constitutive overexpression of HCCR-1 allowed foi a relative amount of resistance to serum deprivation-induced G 0 /G, arrest Following the release of cells from the growth arrest caused by serum-deprivation, there were consistent increases of over 10% m the S-phase populations of HCCR-1 cells as compared to wild-type cells at measured time intervals (12 h, 24 h and 48 h) Therefoie overexpression of HCCR- 1 could deregulate cell growth by shortening the G 0 /G, -phase and increasing the S-phase population of cells Example 18. Construction of anti-sense ohgodeoxmucleotide Anti-sense and sense phosphorothioate olιgodeoxynucleotιde(ODNs) targeting the translation starting site of HCCR- 1 mRNA weie synthesized based on the human HCCR-1 cDNA sequence (GenBank accession numbei AF 195651) by cyanoethylphosphoramidite chemistry on an automated DNA synthesizei (Expedite Nucleic Acid System, Framingham. MA) The sequence of 18-mer HCCR- 1 anti-sense ODN was 5'- CCTGGACATTTTGTCACC-3' (SEQ ID NO 3, corresponding to nucleotide Nos 66 to 83 of SEQ ID NO 1) The corresponding sense sequence, 5'- GGTGACAAAATGTCCAGG-3'(SEQ ID NO 4), and missense sequence, 5'- CGCGGATATTTCCTCACC-3'(SEQ ID NO 5) were used as controls Example 19. Cancer gene therapy using HCCR-1 antisense ODN Step 19- 1 Inhibition of gene expression Exponentially growing 2 X 10 5 H-358 lung carcinoma cells (ATCC CRL-5807) were detached by trypsm-EDTA and seeded in a 24-well plate Lipofectamme (Gibco BRL) was used foi olιgodeoxynucleotιde(ODN) treatment Lipofectamme (5 μl/ml medium) was incubated with an appropriate amount of ODN to achieve a final concentration of 100 nM ODN, in the cell suspension for 30 minutes at room temperature Then l,000μl portions of the mixture were added directly to the cells on the 24-well plates and incubated for 1, 2, 3, 5 and 7 days, respectively There was no cytotoxicirx of the transfection reagent as controlled by trypan blue dye exclusion assay To observe the inhibitory effect of HCCR-1 anti-sense ODN, the cultured lung carcinoma cells were treated with 100 nM each of sense, missense and anti-sense ODNs obtained m Example 18, respectively Inhibition of HCCR-1 expression in anti-sense ODN-treated lung caicmoma cells was demonstrated by reverse transcπption-polymerase chain reaction (RT-PCR) The sequences of oligonucleotide primers used for RT-PCR, synthesized according to the coding region of HCCR-1 cDNA were as follows forward. 5'- GGGAGATGGAGCATTTGAGA-3' (SEQ ID NO 6. corresponding to nucleotides Nos 376-395 of SEQ ID NO 1) and reverse, 5'- GCTTCCGGAAAGCATGATAG-3'(SEQ ID NO 7, complementary to nucleotide Nos 554-573 of SEQ ID NO: l. The dose of anti-sense exerting inhibitory effect was related to the levels of HCCR- 1 mRNA expressιon(Fιg 26A) 497 bp β-actm was used as an internal control to confirm mRNA mtegπty(Fιg 26 B) A negative contιol(N ) contained nuclease-free water instead of RNA template 1000-bp laddei DNA size marker(M) was also used As shown in Fig. 26A, the level of 198 bp HCCR- 1 RT-PCR product decreased in a time-dependent manner by anti- sense ODN treatment HCCR-1 gene expression was completely inhibited in cells treated with 100 nM of anti-sense HCCR-1 ODN for 7 days In contrast, expected 198 bp HCCR-1 RT-PCR product was detected in cells treated with 100 nM of sense or missense HCCR-1 ODN, respectively, and in the untreated parental cells These results show that the treatment with 100 nM of anti-sense HCCR- 1 ODN completely blocks HCCR-1 gene expressions in lung carcinoma cells Step 19-2 Inhibition of cell growth The growth phenotype of H-358 lung cancer cells treated with 100 nM of sense, anti-sense or missense HCCR-1 ohgodeoxynucleotide was assessed by growth curve In three independent experiments, H-358 lung cancel cells weie trypismized and plated m the presence of 100 nM of sense, anti-sense oi missense HCCR-1 ODN obtained m Example 18. and a growth medιum(RPMl- 1640) containing 100 nM of HCCR-1 ODN was replaced eveiy other day Cells in triplicate dishes were detached and viable cells were counted every other da\ using trypan blue dye exclusion As shown in Fig 27, until 1 day of treatment, there were no discernable differences in cell growth among sense( ), mιssense(Δ) or antι-sense(o) HCCR- 1 ODN-treated carcinoma cells However, after 3 days of HCCR- 1 ODN treatment, anti-sense HCCR-1 ODN inhibited lung carcinoma cell giowth in a time-dependent manner After 7 days exposure to antisense HCCR-1 ODN, the extent of giowth inhibition was about 100% for H-358 lung carcinoma cells, while cells exposed to sense or missense HCCR-1 ODN showed growth patterns similar to that of untreated wild-type H-358 cells(control cells, 0) Example 20. HCCR-1 gene as a regulator of embryonic kidney development Because the acquisition of epithelial properties by the fibroblast-deπved HCCR-1 cells mimics the mesenchymal to epithelial conversion of cells during the organogenesis of the kidney (Giordano, S et al , Proc Natl Acad Sci USA 90, 649-653 (1993) Tsarfaty, I , et al , Science 263, 98-101 (1994)), an experiment was conducted to examine whether HCCR-1 is expressed m a developing kidney Total proteins in tissue extracts of fetal 16-, 18- and 20-day rat kidneys, postnatal 1-, 7- and 14-day rat kidneys and adult rat kidney were subjected to SDS-PAGE HCCR-1 protein in HCCR-1 positive bands were detected by ECL- Western blot detection kit employing rat polyclonal anti-HCCR- 1 serum as in Example 14 The result in Fig. 28 demonstrates that HCCR-1 protem having a relative molecular mass of approximately 40,000 (M, ~40K) begins to be overexpressed at fetal 18-day remains at a high expression level up to postnatal 14-day. and decreases to a very low level m adult rat kidney In Fig 28. /< and P denote fetal and postnatal, respectively A 20-day-old fetal rat kidney was subjected to an immunohistochemical staining as m Example 15 As revealed in Fig 29 which shows a stained section of the rat kidney(Magmfication, x 42), HCCR-1 antibody stained the collecting ducts only (medulla on the left side), which are derived from the ureteric bud (Saxen, L Organogenesis of the kidney 88-128 (Cambridge University Press, Cambridge, United Kingdom, 1987), Coles. H S . et al . Development 118, 777-784 (1993)) The developing nephrons in the cortex weie not stained (nephrogenic zone on the right side). Further, a 18-day-old fetal rat kidney was subjected to an immunohistochemical staining as m Example 15 and, then, observed undei a differential-interference contrast microscope As shown in Fig 30, the basolateral plasma membranes of medullary collecting duct were especially reactive to HCCR-1 antιbody(Magnifιcatιon, x 220) Because nephrogenesis is stimulated by a distinct ureteric signal diffusion-limited basolateral molecules (Barasch, J , et al , Am J Physiol 271. F50-F61 ( 1996)), which trigger mesenchymal to epithelial conversion, it is presumed that the HCCR-1 product may be a mesenchyme-deπved regulatory factor (Barasch, J et al , Cell 99, 377-386 (1999) Barasch, J et al , J Clin Invest. 103, 1299-1307 (1999)) that stimulates morphogenesis of epitheha in the kidney developmental process and mediates interactions between mesenchyme and epitheha during neoplastic transformation The present specification includes the appended Sequence Listing of 49 nucleic acid or amino acid sequences Articles of the patent and scientific periodical literature cited herein are hereby incorporated m then entirety by such citation While the embodiments of the subject invention have been descnbed and illustrated, it is obvious that various changes and modifications can be made therein without departing from the spirit of the present invention which should be limited only by the scope of the appended claims n uresT TREATY ON THE INTBSNΛTIOMΛ HEKMNΓΠON or THE urcr -iir QF MKHύOIKiANliMS KM THE PURPOSE OF PATENT mtuCRDUAE INTERNATIONAL FORM RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issue ursuant to Rule 7 1 : KIM, Jin Woo Hvundae Apt 1-8-8W, Angujung-clong, Kangnam-ku, Seoul 135-1 )0, Republic of Korea I . IDENTIFICATION OF THE ICRO Q RGA I! Accession number Ri en by the Idemificatii'-n reference given by the INTERNATIONAL DEPOSITARY DEPOSITOR: AUTHORITY. Escherlchla coli JM109/HCCR1 KCTC 0667BP 0 . SCIENTIFIC DESC RIPTION AND/OR PROPOSED TAX Q ND lC DESIGNATION The microorganism Identified under I above wat accompanied by: I x 1 a scientific description [ ] a proposed tflxonomlr designation ( urk with a eras, where applicable) HI. RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I above, which was received by it on October 11 1999. IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty wa» received by it ,on V . INTERNATIONA I. DEPOSITARY AUTHflRTTY Name: Korean Collection for Type Cultures Signatures ) of persoιi(s) having the power to represent the International Depositary Authority of authorized ofTιcial(s): Address: Korea Research Institute of Bloacience and Biotochnoloπy (KRIBB) <62, Oun-doπg, Yusong-ku. . S. Taejoπ 305-333. BAE, Kyung Sook, Director Republic of Korea Date ! October 14 1999

Claims: What is claimed is : 1 A human cervical cancer 1 protooncogene havmg the base sequence of SEQ ID NO 1 or a fragment thereof 2 The fragment of the protooncogene of claim 1 having a base sequence corresponding to base Nos 9 to 1088 of SEQ ID NO 1 3 A protem having the ammo acid sequence of SEQ ID 2 or a fiagment thereof 4 A vector comprising the protooncogene or fragment of claim 1 5 A microorganism transformed with the vector of claim 4 6 The microorganism of claim 5, which is E coli JM 109/HCCR- 1 (Accession No KCTC 0667BP) 7 A process for preparing the protein or fragment of claim 3 comprising culturmg the microorganism of claim 5 or 6 8 A kit for diagnosis of cancer which comprises the protooncogene or fragment of claim 1 or 2 9 A kit for diagnosis of cancer which comprises the protem or fragment of claim 3 10 An anti-sense gene having a base sequence which is complementary to the sequence of the full or partial mRNA transcribed from the protooncogene or fragment of claim 1 oi 2 and being capable of binding the mRNA to inhibit the expression of said protooncogene or fragment. 11. The anti-sense gene of claim 10 having the base sequence of SEQ ID NO: 3. 12. A process for treating or preventing cancer in human which comprises administering a therapeutically effective amount of the anti-sense gene of claim 10 or 11 to the human.

Inventors: KIM JIN WOO, KIM, JIN, WOO
Applicants: KIM JIN WOO, KIM, JIN, WOO
Application year: 2000
Main classification: C07K14
IPC codes: A61K31, A61K48, A61P35, C07K14, C12N1, C12N15, C12P21, C12Q1, C12R1